Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 4
1990 5
1991 3
1992 4
1993 7
1994 11
1995 12
1996 26
1997 26
1998 20
1999 25
2000 22
2001 28
2002 37
2003 41
2004 43
2005 57
2006 59
2007 61
2008 47
2009 50
2010 52
2011 41
2012 73
2013 58
2014 61
2015 58
2016 59
2017 50
2018 44
2019 54
2020 55
2021 58
2022 50
2023 3
Text availability
Article attribute
Article type
Publication date

Search Results

1,158 results
Results by year
Filters applied: . Clear all
Page 1
Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial.
Vaishampayan UN, Heilbrun LK, Monk P 3rd, Tejwani S, Sonpavde G, Hwang C, Smith D, Jasti P, Dobson K, Dickow B, Heath EI, Semaan L, Cher ML, Fontana JA, Chinni S. Vaishampayan UN, et al. JAMA Netw Open. 2021 Jan 4;4(1):e2034633. doi: 10.1001/jamanetworkopen.2020.34633. JAMA Netw Open. 2021. PMID: 33496795 Free PMC article. Clinical Trial.
OBJECTIVE: To compare the efficacy of enzalutamide vs bicalutamide in combination with ADT in men with mHSPC, with a subset analysis of Black patients. ...The 12-month PSA response rates were 84% with enzalutamide and 34% with bicalutamide. CONCLUSIONS AND RELEVANCE …
OBJECTIVE: To compare the efficacy of enzalutamide vs bicalutamide in combination with ADT in men with mHSPC, with a subset analysis …
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung D, Higano CS. Penson DF, et al. J Clin Oncol. 2016 Jun 20;34(18):2098-106. doi: 10.1200/JCO.2015.64.9285. Epub 2016 Jan 25. J Clin Oncol. 2016. PMID: 26811535 Clinical Trial.

RESULTS: Enzalutamide reduced the risk of progression or death by 76% compared with bicalutamide (hazard ratio [HR], 0.24; 95% CI, 0.18 to 0.32; P < .001). ...CONCLUSION: Enzalutamide significantly reduced risk of prostate cancer progression or death compared with bi

RESULTS: Enzalutamide reduced the risk of progression or death by 76% compared with bicalutamide (hazard ratio [HR], 0.24; 95% CI, 0. …
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM; NRG Oncology RTOG. Shipley WU, et al. N Engl J Med. 2017 Feb 2;376(5):417-428. doi: 10.1056/NEJMoa1607529. N Engl J Med. 2017. PMID: 28146658 Free PMC article. Clinical Trial.
The cumulative incidence of metastatic prostate cancer at 12 years was 14.5% in the bicalutamide group, as compared with 23.0% in the placebo group (P=0.005). ...Gynecomastia was recorded in 69.7% of the patients in the bicalutamide group, as compared with 10.9% of …
The cumulative incidence of metastatic prostate cancer at 12 years was 14.5% in the bicalutamide group, as compared with 23.0% in the …
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.
Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D, van Os S, Hasabou N, Wang F, Bhattacharya S, Heidenreich A. Shore ND, et al. Lancet Oncol. 2016 Feb;17(2):153-163. doi: 10.1016/S1470-2045(15)00518-5. Epub 2016 Jan 14. Lancet Oncol. 2016. PMID: 26774508 Clinical Trial.
Of the most common adverse events, those occurring more frequently with enzalutamide than with bicalutamide were fatigue (51 [28%] of 183 patients in the enzalutamide group vs 38 [20%] of 189 in the bicalutamide group), back pain (35 [19%] vs 34 [18%]), and hot flus …
Of the most common adverse events, those occurring more frequently with enzalutamide than with bicalutamide were fatigue (51 [28%] of …
The ERα-NRF2 signalling axis promotes bicalutamide resistance in prostate cancer.
Tian L, Peng Y, Yang K, Cao J, Du X, Liang Z, Shi J, Zhang J. Tian L, et al. Cell Commun Signal. 2022 Nov 14;20(1):178. doi: 10.1186/s12964-022-00979-0. Cell Commun Signal. 2022. PMID: 36376959 Free PMC article.
Although patients initially show effective responses to bicalutamide treatment, resistance to bicalutamide frequently occurs and leads to the development of castration-resistant PCa (CRPC). ...Activation of the ERalpha-NRF2 signalling axis contributes to bicaluta
Although patients initially show effective responses to bicalutamide treatment, resistance to bicalutamide frequently occurs a …
Bicalutamide: clinical pharmacokinetics and metabolism.
Cockshott ID. Cockshott ID. Clin Pharmacokinet. 2004;43(13):855-78. doi: 10.2165/00003088-200443130-00003. Clin Pharmacokinet. 2004. PMID: 15509184 Review.
Bicalutamide in faeces is thought to arise from hydrolysis of bicalutamide glucuronide and from unabsorbed drug. Bicalutamide appears to be cleared almost exclusively by metabolism; this is largely mediated by cytochrome P450 (CYP) for (R)-bicalutamide
Bicalutamide in faeces is thought to arise from hydrolysis of bicalutamide glucuronide and from unabsorbed drug. Bicalutami
Bicalutamide: in early-stage prostate cancer.
Carswell CI, Figgitt DP. Carswell CI, et al. Drugs. 2002;62(17):2471-79; discussion 2480-1. doi: 10.2165/00003495-200262170-00006. Drugs. 2002. PMID: 12421104 Review.
Bicalutamide recipients reported a significantly smaller loss in sexual interest and a better physical capacity than recipients of castration (p <or= 0.05 for both parameters). Bicalutamide is well tolerated in studies of up to 6.3 years' duration....
Bicalutamide recipients reported a significantly smaller loss in sexual interest and a better physical capacity than recipients of ca
[Bicalutamide].
Taéron C. Taéron C. Rev Infirm. 2010 Mar;(158):47-9. Rev Infirm. 2010. PMID: 20383962 French. No abstract available.
Bicalutamide dosages used in the treatment of prostate cancer.
Kolvenbag GJ, Nash A. Kolvenbag GJ, et al. Prostate. 1999 Apr 1;39(1):47-53. doi: 10.1002/(sici)1097-0045(19990401)39:1<47::aid-pros8>3.0.co;2-x. Prostate. 1999. PMID: 10221266 Review.
Furthermore, investigations of higher doses of bicalutamide have justified evaluation of bicalutamide 150 mg as monotherapy. ...CONCLUSIONS: On the basis of available data, bicalutamide 50 mg is an appropriate dose to use in combined androgen blockade, …
Furthermore, investigations of higher doses of bicalutamide have justified evaluation of bicalutamide 150 mg as monotherapy. . …
1,158 results